All Cured of Hep C Genotype 2 or 3 in Arm of PSI-7977 Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Financial Help for Old and New Hepatitis C Drugs

Back to News Homepage
Next

Liver Fibrosis Reduced with HIV-Hep C Co-Infection

All Cured of Hep C Genotype 2 or 3 in Arm of PSI-7977 Trial

The Editors at Hepatitis Central
July 22, 2011

Print this page

In a Phase 2b study with pegylated interferon and ribavirin, Pharmasset’s PSI-7977 had a 100 percent success rate against Hepatitis C genotypes 2 and 3.

Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3

— 24 out of 24 subjects with HCV genotype 2 or 3 achieved an SVR after 12 weeks of treatment with PSI-7977 400mg QD and pegylated interferon and ribavirin

— SVR12 results from PROTON in HCV genotype 1 subjects are expected in second half of 2011

PRINCETON, N.J., July 20, 2011 /PRNewswire/ — Pharmasset, Inc. (Nasdaq: VRUS) announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously. Twenty four out of twenty four subjects (100%) who completed treatment achieved an SVR, defined as HCV RNA below the limit of detection (<15 IU/ml) 24 weeks after the completion of treatment. No subject exhibited breakthrough on treatment or relapse after treatment.

Continue reading this entire article:
http://www.prnewswire.com/news-releases/pharmasset-announces-final-svr-data-from-proton-trial-with-psi-7977-in-subjects-infected-with-hepatitis-c-infection-genotype-2-or-3-125877113.html

1 Comment
Share
Share
Previous

Financial Help for Old and New Hepatitis C Drugs

Back to News Homepage
Next

Liver Fibrosis Reduced with HIV-Hep C Co-Infection

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.